Passionate about Progress
We are a clinical-stage biopharmaceutical company that is developing the investigational therapy Haduvio™ (oral nalbuphine ER) to help patients suffering with chronic cough by targeting the central and peripheral cough reflex arc.
We released positive results from our Phase 2a RIVER trial for the treatment of refractory chronic cough (RCC) in March 2025 and are currently conducting the Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough, with topline results expected in the second quarter of 2025.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT and we are proud to be part of its vibrant life-science community.
“At Trevi Therapeutics, we are dedicated to the development of Haduvio for patients with chronic cough in Idiopathic Pulmonary Fibrosis and Refractory Chronic Cough. Our team is committed to improving patients’ lives. Each day, we work with the purpose of making a meaningful impact, focused on delivering a therapy for those affected by chronic cough.”
– Jennifer Good, Co-Founder, President & CEO